Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Budenofalk 4 mg Zäpfchen, placebo to test
Dr. Falk Pharma GmbH
Acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma
1 trial -
Budesonide
LIGAND PHARMACEUTICALS INC
Seasonal Allergic Rhinitis
1 trial -
Budesonide + Azelastine
LIGAND PHARMACEUTICALS INC
Seasonal Allergic Rhinitis
1 trial -
C16G2
Armata Pharmaceuticals
Dental Caries
3 trials -
C16G2 Gel
Armata Pharmaceuticals
Dental Caries
1 trial -
C16G2 Rinse
Armata Pharmaceuticals
Dental Caries
1 trial -
C16G2 Strip
Armata Pharmaceuticals
Dental Caries
1 trial -
C16G2 Varnish
Armata Pharmaceuticals
Dental Caries
1 trial -
CAMPTO 20 mg/mL concentrate for solution for infusion, Futibatinib, Leucovorin-Teva 10 mg/ml Concentrate for Solution for Infusion, FLUOROURACIL, CISPLATIN, OXALIPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Taiho Pharma Netherlands B.V.
Solid Tumors
1 trial -
CAPECITABINE, CAPECITABINE, TRIPTORELIN, [177Lu]-NeoB solution for infusion, LEUPRORELIN, AAA503, GOSERELIN
Novartis Pharmaceuticals
Breast Cancer
1 trial -
CARBOCAINE 20 mg/ml, solution injectable
Pari Pharma GmbH
Ischemic stroke
1 trial -
CARBOPLATIN , PACLITAXEL , NP137, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Lacuna Pharma Pty Ltd
Patiens with locally advanced/metastatic endometrial carcinoma or cervix carcinoma progressing/relapsing after at least one prior systemic chemotherapy.
1 trial -
CBD 400 mg
Jazz Pharmaceuticals Ireland Limited
Opiate Addiction
1 trial -
CBD Oral Solution
Jazz Pharmaceuticals Ireland Limited
Fragile X Syndrome
1 trial -
CBD Oral Solution (eCBD system Target)
Jazz Pharmaceuticals Ireland Limited
Fragile X Syndrome
1 trial -
CC-92480, Dexamethason acis 8 mg Tabletten, Dexamethason 8 mg JENAPHARM®, CC-92480, CC-92480, CC-92480, CC-92480, CC-92480, CC-92480, Dexamethason 4 mg JENAPHARM®, Dexamethason-ratiopharm® 4 mg Tabletten
Celgene Europe Limited
Relapsed and refractory multiple myeloma (RRMM)
1 trial -
CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib
Pharming Technologies B.V.
primary immunodeficiency
1 trial -
CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib
Pharming Technologies B.V.
Common variable immunodeficiency
1 trial -
CE-Iohexol
LIGAND PHARMACEUTICALS INC
Contrast-induced Nephropathy
1 trial -
CEFAZOLIN, CLOXACILLIN, CLAVULANIC ACID, AMOXICILLIN, AMOXICILLIN
Pari Pharma GmbH
acute osteomyelitis of the child
1 trial -
CEFEPIME , AMIKACIN , PIPERACILLIN AND BETA-LACTAMASE INHIBITOR
Pari Pharma GmbH
gram-negative bacillus pneumonia acquired during mechanical ventilation in patients receiving Extracorporeal Membrane veno-arterial oxygenation
1 trial -
CEP-18770
Teva Pharma GmbH
Multiple Myeloma
2 trials -
CEP-37247
Teva Pharma GmbH
Sciatica
1 trial -
CEP-701
Teva Pharma GmbH
Acute Myeloid Leukemia
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources